A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol
Abstract Background Treatment decision-making in patients with relapsed/refractory multiple myeloma (RRMM) is challenging for a number of reasons including, the heterogeneity of disease at relapse and the number of possible therapeutic approaches. This study broadly aims to generate new evidence-bas...
Main Authors: | Fabio Efficace, Mario Boccadoro, Antonio Palumbo, Maria Teresa Petrucci, Francesco Cottone, Laura Cannella, Elena Zamagni, Pasquale Niscola, Charalampia Kyriakou, Tommaso Caravita, Massimo Offidani, Franco Mandelli, Michele Cavo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-06-01
|
Series: | Health and Quality of Life Outcomes |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12955-018-0953-4 |
Similar Items
-
Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
by: Sonia Morè, et al.
Published: (2020-11-01) -
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
by: Massimo Offidani, et al.
Published: (2021-02-01) -
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight
by: Claudia Ielo, et al.
Published: (2024-01-01) -
Plasmablastic myeloma progressed to plasma cell leukaemia
by: Ke Xu, et al.
Published: (2021-11-01) -
Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)